Logo-apb
Adv Pharm Bull. 2022;12(2): 262-273.
doi: 10.34172/apb.2022.027
  Abstract View: 590
  PDF Download: 220

Review Article

CRISPER/CAS System, a Novel Tool of Targeted Therapy of Drug-Resistant Lung Cancer

Vahid Akbari Kordkheyli 1 ORCID logo, Mohsen Rashidi 2, Yasaman Shokri 3, Samane Fallahpour 3, Atena Variji 3, Ehsan Nabipour Ghara 4, Sayed Mostafa Hosseini 5* ORCID logo

1 Student Research Committee, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
2 Department of Pharmacology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
3 Department of Clinical Biochemistry and Genetics, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
4 Department of Biochemistry-Genetic and Plant Biology, Faculty of Basic Sciences, Islamic Azad University, Damghan Branch, Damghan, Iran.
5 Human Genetic Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
*Corresponding Author: Sayed Mostafa Hosseini, Tel: (021)87559800, Email: Geneticman2005@gmail.com

Abstract

Lung cancer (LC) is the most common cause of cancer-related death worldwide. Patients with LC are usually diagnosed at advanced phases. Five-year survival rate in LC patients is approximately 16%. Despite decades of research on LC treatments, clinical outcomes are still very poor, necessitating to develop novel technologies to manage the disease. Considering the role of genetic and epigenetic changes in oncogenes and tumor-suppressor genes in cancer progression, gene therapy provides a hot spot in cancer treatment research. Gene therapy offers less side effects compared to conventional methods such as chemotherapy. Unlike the traditional approaches of gene therapy that have temporary effects, using genetic modification tools can offer persistent cure. Over the past a few years, many studies have effectively used the CRISPR–Cas9 approach to modify gene expression in cells. This system is applied to induce site-specific mutagenesis and epigenetic modifications and regulate gene expression. In this review, we discuss recent applications of the CRISPR–Cas9 technology in treating LC.
Keywords: CRISPR/CAS, Lung, Cancer, Genetic modification

First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 591

Your browser does not support the canvas element.


PDF Download: 220

Your browser does not support the canvas element.

Submitted: 13 Dec 2020
Revision: 04 Mar 2021
Accepted: 31 Mar 2021
ePublished: 03 Apr 2021
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)